Adicet Bio, Inc.
General ticker "ACET" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $51.4M (TTM average)
Adicet Bio, Inc. follows the US Stock Market performance with the rate: 9.4%.
Estimated limits based on current volatility of 4.2%: low 4.77$, high 5.19$
Factors to consider:
- Total employees count: 102 (-32.9%) as of 2025
- Top business risk factors: Limited operating history, Clinical trial failure, Regulatory and compliance, Manufacturing issues, Inability to raise capital
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.70$, 14.50$]
- 2026-12-31 to 2027-12-31 estimated range: [2.87$, 9.56$]
Financial Metrics affecting the ACET estimates:
- Negative: with PPE of -0.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 82.77 > 81.92
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: 0 < Industry inventory ratio change (median), % of 0
Short-term ACET quotes
Long-term ACET plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $152.04MM | $127.61MM | $122.11MM |
| Operating Income | $-152.04MM | $-127.61MM | $-122.11MM |
| Non-Operating Income | $9.38MM | $10.49MM | $5.31MM |
| Interest Expense | $0.03MM | $0.00MM | $0.04MM |
| R&D Expense | $106.04MM | $99.32MM | $99.13MM |
| Income(Loss) | $-142.66MM | $-117.12MM | $-116.80MM |
| Net Income(Loss)* | $-142.66MM | $-117.12MM | $-116.80MM |
| Stockholders Equity | $170.18MM | $186.61MM | $159.21MM |
| Assets | $207.29MM | $220.22MM | $192.35MM |
| Operating Cash Flow | $-93.72MM | $-92.38MM | $-95.25MM |
| Capital expenditure | $4.46MM | $1.12MM | $1.74MM |
| Investing Cash Flow | $-4.46MM | $-119.24MM | $2.39MM |
| Financing Cash Flow | $0.24MM | $111.31MM | $75.25MM |
| Earnings Per Share** | $-53.03 | $-21.33 | $-16.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.